EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adherence to antiretroviral therapy and drug resistance impact evolving viral suppression among a cohort of children and adolescents living with perinatal HIV infection in western Kenya

Rachel Vreeman iD, Winstone Nyandiko, Allison DeLong, Ashley Chory, Michael Scanlon, Josephine Aluoch, Edwin Sang, Vladimir Novitsky, Festus Sang iD, Celestine Ashimosi, Samuel Ayaya, Eslyne Jepkemboi und 3 weitere

PLOS One · 2026

DOI: 10.1371/journal.pone.0355492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Rachel Vreeman und 14 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, New York, United States of America. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Foundation for the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We characterize antiretroviral therapy (ART) adherence among children and adolescents living with perinatal HIV (CALWH) and investigate its impact on treatment failure (TF) and drug resistance (DR).

Methods

We enrolled Kenyan CALWH ≤15 years on NNRTI-based ART and monitored adherence over six months, with monthly, validated questionnaires and continuous MEMs (Medication Event Monitoring Systems) electronic dose monitoring. We assessed associations between TF (viral load (VL) >1,000 copies/mL; local guidelines) at 1 month (Blood Draw 1, BD1) and, for a subset, at 4 months (Blood Draw 2, BD2) and adherence using weighted logistic regression. Sanger genotyping identified reverse transcriptase DR mutations upon TF. Associations between number of mutations and adherence was modelled by weighted Poisson regression.

Results

Among 692 CALWH (51% female; mean 8.4 years) on ART for mean 2.6 years between 2010−2013, 44% reported non-adherence at baseline. At BD1, 21% (N = 143/464) had TF. Reported non-adherence at enrollment and lower MEMS adherence between enrollment and BD1 were significantly associated with TF at BD1 (respectively, OR=1.25 per 1 unit higher non-adherence, 95% CI = 1.05 to 1.48, and OR=0.69 per 1 unit z-score higher MEMS adherence, 95% CI = 0.50 to 0.95). Among those with TF at BD1, 43% (31/72) had TF at BD2, higher MEMS adherence no longer predicted VL suppression. DR genotyping among those with TF at BD1 found fewer mutations for those without treatment interruption >48 hours (RR = 0.17, CI = 0.05 to 0.61), but among them, more mutations for those with longer interruptions (hours, log-10 RR = 2.48, CI = 1.10 to 5.59). More resistance was also associated with longer ART years (Log-10 RR = 1.47, CI = 1.15 to 1.89), and higher log-10 VL at BD1 (RR = 1.21, CI = 1.06 to 1.37)). MEMS adherence had significant, U-shaped relationship, with most mutations at lower (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsDrug Resistance, ViralAnti-HIV AgentsHumansFemaleKenyaChildAdolescentViral LoadMaleHIV-1MutationChild, PreschoolCohort StudiesDrug Monitoring

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
  • Arnhold Institute for Global Health, New York, New York, United States of America.
  • Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.
  • Moi University, Eldoret, Kenya.
  • Brown University School of Public Health, Providence, Rhode Island, United States of America.
  • Global Health Program, College of Liberal Arts and Sciences, DePauw University, Greencastle, Indiana, United States of America.

ORCID-Profile: Rachel Vreeman, Festus Sang, Rami Kantor

Förderung

  • NIAID NIH HHS
  • Foundation for the National Institutes of Health

Zitieren

APA

Vreeman, R., Nyandiko, W., DeLong, A., Chory, A., Scanlon, M., Aluoch, J., Sang, E., Novitsky, V., Sang, F., Ashimosi, C., Ayaya, S., Jepkemboi, E., Orido, M., Hogan, J., & Kantor, R. (2026). Adherence to antiretroviral therapy and drug resistance impact evolving viral suppression among a cohort of children and adolescents living with perinatal HIV infection in western Kenya. PLOS One. https://doi.org/10.1371/journal.pone.0355492

Vancouver

Vreeman R, Nyandiko W, DeLong A, Chory A, Scanlon M, Aluoch J, et al. Adherence to antiretroviral therapy and drug resistance impact evolving viral suppression among a cohort of children and adolescents living with perinatal HIV infection in western Kenya. PLOS One. 2026. doi:10.1371/journal.pone.0355492

BibTeX
@article{Vreeman2026,
  author = {Vreeman, Rachel and Nyandiko, Winstone and DeLong, Allison and Chory, Ashley and Scanlon, Michael and Aluoch, Josephine and Sang, Edwin and Novitsky, Vladimir and Sang, Festus and Ashimosi, Celestine and Ayaya, Samuel and Jepkemboi, Eslyne and Orido, Millicent and Hogan, Joseph and Kantor, Rami},
  title = {Adherence to antiretroviral therapy and drug resistance impact evolving viral suppression among a cohort of children and adolescents living with perinatal HIV infection in western Kenya},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0355492}
}
Kostenlos starten →